Accueil>>Signaling Pathways>> DNA Damage/DNA Repair>> DNA/RNA Synthesis>>L67

L67 (Synonyms: DNA Ligase Inhibitor)

Catalog No.GC18186

L67 (DNA Ligase Inhibitor) est un inhibiteur compétitif de l'ADN ligase qui inhibe efficacement les ADN ligases I/III (les deux IC50 sont de 10 μM). L67 (inhibiteur d'ADN ligase) peut causer des dommages À l'ADN nucléaire en réduisant les niveaux d'ADN mitochondrial et en augmentant les niveaux de ROS générés par les mitochondries. L67 (DNA Ligase Inhibitor) active également la voie de l'apoptose dépendante de la caspase 1 dans les cellules cancéreuses, peut être utilisé dans la recherche sur le cancer.

Products are for research use only. Not for human use. We do not sell to patients.

L67 Chemical Structure

Cas No.: 325970-71-6

Taille Prix Stock Qté
5mg
103,00 $US
En stock
10mg
168,00 $US
En stock
25mg Please Inquire Please Inquire
50mg
612,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products
L67 is a competitive inhibitor of DNA ligases I and III (IC50s = 10 and 10 uM for human DNA ligase I and human ligase IIIβ). It blocks DNA binding (Ki = 10 uM), increasing the cytotoxicity of DNA-damaging agents. It also inhibits mitochondrial DNA ligase IIIα and induces the production of reactive oxygen species (ROS) and apoptosis in cancerous, but not non-malignant, cells. It does not inhibit DNA ligase IV or T4 DNA ligase at concentrations up to 100 uM.

Avis

Review for L67

Average Rating: 5 ★★★★★ (Based on Reviews and 8 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for L67

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.